Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544389 | 0.83 | CHRNB2 (0.44) | GRM5CHRNB2CHRNA5CHRNA4PSEN1 | |
| SCHEMBL5485357 | 0.82 | CHRNB2 (0.45) | GRM5CHRNB2CHRNA5CHRNA4PSEN1 | |
| SCHEMBL1544334 | 0.79 | USP30 (0.47) | GRM5CHRNB2CHRNA5CHRNA4PSEN1 | |
| SCHEMBL5491291 | 0.76 | CHRNB2 (0.39) | CHRNB2CHRNA5CHRNA4PSEN1PSEN2 | |
| SCHEMBL1545926 | 0.75 | CPT2 (0.37) | GRM5CHRNB2CHRNA5CHRNA4PSEN1 | |
| SCHEMBL4223764 | 0.73 | PSEN1 (0.37) | GRM5CHRNB2CHRNA5CHRNA4PSEN1 | |
| SCHEMBL5482293 | 0.72 | P2RX7 (0.40) | GRM5CHRNB2CHRNA5CHRNA4USP30 | |
| SCHEMBL1544442 | 0.70 | KCNH2 (0.47) | GRM5 | |
| SCHEMBL5478892 | 0.69 | MAPT (0.40) | GRM5USP30 | |
| SCHEMBL4327916 | 0.68 | KCNH2 (0.47) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027129-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130824-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | GRM5 1/4885CHRNB2 254/4885CHRNA5 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.